Immune thrombocytopenia patients requiring anticoagulation-maneuvering between scylla and charybdis

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Matzdorff, Axel ^a   Beer, Juerg Hans ^b  

^a Caritasclinic Saarbruecken ^*  (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CORTICOSTEROID; DEXAMETHASONE; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; ROMIPLOSTIM; THIENOPYRIDINE DERIVATIVE; TRANEXAMIC ACID;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CARDIOVASCULAR SURGERY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PLASMAPHERESIS; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSLUMINAL CORONARY ANGIOPLASTY; VENOUS THROMBOEMBOLISM;

ALGORITHMS; ANTICOAGULANTS; HUMANS; THROMBOCYTOPENIA;

EID: 84877684740     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.020     Document Type: Article

References (82)

1. Frederiksen H., Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999, 94:909-913.
2. Neylon A.J., Saunders P.W., Howard M.R., Proctor S.J., Taylor P.R. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003, 122:966-974. on behalf of the Northern Region Haematology Group.
3. Segal J.B., Powe N.R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006, 4:2377-2383.
4. Landgren O., Gridley G., Fears T.R., Caporaso N. Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and white veterans. Blood 2006, 108:1111-1112.
5. Feudjo-Tepie M.A., Robinson N.J., Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008, 6:711-712.
6. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
7. Shen A.Y., Contreras R., Sobnosky S., et al. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults- a cross-sectional study. J Natl Med Assoc 2010, 102:906-913.
8. MMWR Morb Mortal Wkly Rep 2012, 61:379-382. Prevalence of Stroke-United States, 2006-2010.
9. MMWR Morb Mortal Wkly Rep 2011, 60:1377-1381. Prevalence of coronary heart disease-United States, 2006-2010.
10. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998, 158:585-593.
11. Dobromirski M., Cohen A.T. How I manage venous thromboembolism risk in hospitalized medical patients. Blood 2012, 120:1562-1569.
12. Khellaf M., Michel M., Quittet P., et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011, 118:4338-4345.
13. Almakadi M., Chan A.K.C., Chan H.H.W. Anticoagulant therapy in patients with thrombocytopenia: a systematic review of case series in medical literature. J Thromb Haemost 2011, 9(Suppl 2):636. [abstr P-WE-372].
14. Kühne T., Berchtold W., Michaels L.A., et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011, 96:1831-1837.
15. Sarpatwari A., Bennett D., Logie J.W., et al. Thromboembolic events among adult patients with primary immune thrombocytopenia (ITP) in the United Kingdom General Practice Research Database. Haematologica 2010, 95:1167-1175.
16. Nørgaard M., Severinsen M.T., Mægbæk M.L., et al. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2012, 159:109-111.
17. Severinsen M.T., Engebjerg M.C., Farkas D.K., et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011, 152:360-362.
18. Thachil J., Callaghan T., Martlew V. Thromboembolic events are not uncommon in patients with immune thrombocytopenia. Br J Haematol 2010, 150:496-497.
19. Aledort L.M., Hayward C.P., Chen M.G., et al. ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts. Am J Hematol 2004, 76:205-213.
20. Feudjo-Tepie MA, Le Roux G, Beach KJ, Bennett D, Robinson NJ. Comorbidities of idiopathic thrombocytopenic purpura: a population-based study. Adv Hematol. 2009;2009:963506.
21. Ahn Y.S., Horstman L.L., Jy W., et al. Vascular dementia in patients with immune thrombocytopenic purpura. Thromb Res 2002, 107:337-344.
22. Psaila B., Bussel J.B., Frelinger A.L., et al. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost 2011, 9:2302-2310.
23. Paran D., Herishanu Y., Elkayam O., Shopin L., Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005, 16:313-318.
24. Sartori T.M., Maurizio P.G., Sara P., et al. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. J Heart Lung Transplant 1999, 18:693-700.
25. Brotman D.J., Girod J.P., Posch A., et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006, 118:247-252.
26. Endo Y., Nishimura S., Miura A. Deep vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura. JAMA 1988, 259:3561-3562.
27. Wun T, Boyle SF, Brunson A, White RH. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2011;118 (ASH annual meeting abstracts);1412 [abstr 3284].
28. Thomsen R.W., Schoonen W.M., Farkas D.K., Riis A., Fryzek J.P., Sørensen H.T. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 2010, 8:1413-1416.
29. Dultz G., Kronenberger B., Azizi A., et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011, 55:229-232.
30. Przespo E., Elefante A. Deep vein thrombosis associated with a single dose of romiplostim in a high-risk patient. Am J Health Syst Pharm 2012, 69:131-133.
31. Gernsheimer T.B., George J.N., Aledort L.M., et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010, 8:1372-1382.
32. Bussel J.B., Cheng G., Saleh M.N., et al. Incidence of thromboembolic events across eltrombopag clinical trials in chronic immune thrombocytopenia (ITP). Blood 2010, 116. (ASH annual meeting abstracts):37 [abstr 70].
33. Ghanima W., Lee S.Y., Barsam S., et al. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol 2012, 158:798-814.
34. Cantoni N., Heizmann M., Bargetzi M. Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment. Br J Haematol 2012, 157:639-641.
35. Kikuchi M., Niimi T., Yamamoto T., Hasegawa R., Banno S., Nitta M. Acute myocardial infarction with idiopathic thrombocytopenic purpura in an elderly patient. Nihon Ronen Igakkai Zasshi 1996, 33:867-870.
36. Paolini R., Zamboni S., Ramazzina E., Zampieri P., Cella G. Idiopathic thrombocytopenic purpura treated with steroid therapy does not prevent acute myocardial infarction: a case report. Blood Coagul Fibrinolys 1999, 10:439-442.
37. Paolini R., Fabris F., Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 2000, 65:177-178.
38. Fruchter O., Blich M., Jacob G. Fatal acute myocardial infarction during severe thrombocytopenia in a patient with idiopathic thrombocytopenic purpura. Am J Med Sci 2002, 323:279-280.
39. Neskovic A., Stankovic I., Miliecevic P., et al. Primary PCI for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. Herz 2000, 35:43-49.
40. Marõnas J.M., Llamas P., Caffarena J.M. Mitral valve replacement and splenectomy in a patient with chronic idiopathic thrombocytopenic purpura. Thorac Cardiovasc Surg 1982, 30:407-408.
41. Koike R., Suma H., Oku T., Satoh H., Sawada Y., Takeuchi A. Combined coronary revascularization and splenectomy. Ann Thorac Surg 1989, 48:853-854.
42. Iida H., Kitamura N., Yamaguchi A., Fukushima Y., Ohtaki M., Minoji T.A.-C. bypass grafting and ligation of coronary arteriovenous fistula in a patient with idiopathic thrombocytopenic purpura. Nihon Kyobu Geka Gakkai Zasshi 1988, 36:2296-2300.
43. Thompson L.D., Cohen A.J., Edwards F.H., Barry M.J. Coronary artery bypass in idiopathic thrombocytopenia without splenectomy. Ann Thorac Surg 1989, 48:721-722.
44. Bowman G.A. Coronary artery bypass grafting without splenectomy. Ann Thorac Surg 1990, 50:330-331.
45. Briffa N.P., Dyde J.A., Harris R.I. Heart operation in a patient with refractory idiopathic thrombocytopenic purpura. J Thorac Cardiovasc Surg 1994, 107:316-317.
46. Mathew T.C., Vasudevan R., Leb L., Pezzella S.M., Pezzella A.T. Coronary artery bypass grafting in immune thrombocytopenic purpura. Ann Thorac Surg 1997, 64:1059-1062.
47. Kojima Y., Itoh H., Fukushima T. Perioperative management of patients with idiopathic thrombocytopenic purpura. Nihon Rinsho 2003, 61:632-637.
48. Oba J., Aoki H., Yoshida T., Kanaoka T., Oe K. Mitral valve replacement in a patient with idiopathic thrombocytopenic purpura. Jpn J Thorac Cardiovasc Surg 2000, 48:129-131.
49. Jubelirer S.J., Mousa L., Reddy U., Mir M., Welch C.A. Coronary artery bypass grafting (CABG) in patients with immune thrombocytopenia (ITP): a community hospital experience and review of the literature. W V Med J 2011, 107:10-14.
50. Caputo R.P., Abraham S., Churchill D. Transradial coronary stent placement in a patient with severe idiopathic autoimmune thrombocytopenic purpura. J Invasive Cardiol 2000, 12:365-368.
51. Kikuchi S., Hayashi Y., Fujioka S., Kukita H., Ochi N. A case of intracoronary stent implanted for acute myocardial infarction in an elderly patient with idiopathic thrombocytopenic purpura. Nihon Ronen Igakkai Zasshi 2002, 39:88-93.
52. Stouffer G.A., Hirmerova J., Moll S., Rubery B., Napoli M., Ohman E.M., Simpson R. Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura. Catheter Cardiovasc Interv 2004, 61:364-367.
53. Moretti C., Teresa Lucciola M., et al. Idiopathic thrombocytopenic purpura and percutaneous coronary stenting: a dangerous duo?. Int J Cardiol 2008, 130:e96-e97.
54. Nurkalem Z., Işik T., Cinar T., Ergelen M. Primary coronary intervention for acute ST-elevation myocardial infarction in a patient with immune thrombocytopenic purpura. Turk Kardiyol Dern Ars 2011, 39:414-417.
55. Rhee H.Y., Choi H.Y., Kim S.B., Shin W.C. Recurrent ischemic stroke in a patient with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis 2010, 30:229-232.
56. De La Peña A., Fareed J., Thethi I., Morales-Vidal S., Schneck M.J., Shafer D. Ischemic stroke in the setting of chronic immune thrombocytopenia in an elderly patient-a therapeutic dilemma. Clin Appl Thromb Hemost 2012, 18:324-326.
57. Theeler B.J., Ney J.P. A patient with idiopathic thrombocytopenic purpura presenting with an acute ischemic stroke. J Stroke Cerebrovasc Dis 2008, 17:244-245.
58. McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004, 104:956-960.
59. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., Nichol J.L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009, 113:2161-2171.
60. Cuker A., Cines D.B. How I treat heparin-induced thrombocytopenia. Blood 2012, 119:2209-2218.
61. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116:4060-9.
62. Giannakopoulos B., Krilis S.A. How I treat the antiphospholipid syndrome. Blood 2009, 114:2020-2030.
63. Thachil J., Toh C.H. Current concepts in the management of disseminated intravascular coagulation. Thromb Res 2012, 129(Suppl 1):S54-S59.
64. Gruel Y., Pacouret G., Bellucci S., Caen J. Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant successfully treated with a low molecular weight heparin. Blood 1997, 90:888-890.
65. Rezende S.M. Secondary prophylaxis with warfarin for recurrent thrombosis in a patient with Glanzmann thrombasthenia and F5 G1691A. Br J Haematol 2012, 156:144.
66. Ten Cate H., Brandjes D.P., Smits P.H., van Mourik J.A. The role of platelets in venous thrombosis: a patient with Glanzmann's thrombasthenia and a factor V Leiden mutation suffering from deep venous thrombosis. J Thromb Haemost 2003, 1:394-395.
67. Phillips R., Richards M. Venous thrombosis in Glanzmann's thrombasthenia. Haemophilia 2007, 13:758-759.
68. Seretny M., Senadheera N., Miller E., Keeling D. Pulmonary embolus in Glanzmann's thrombasthenia treated with warfarin. Haemophilia 2008, 14:1138-1139.
69. Girolami A., Vettore S., Vianello F., Berti de Marinis G., Fabris F. Myocardial infarction in two cousins heterozygous for ASN41HIS autosomal dominant variant of Bernard-Soulier syndrome. J Thromb Thrombolysis 2012, 34:513-517.
70. Humphries J.E., Yirinec B.A., Hess C.E. Atherosclerosis and unstable angina in Bernard-Soulier syndrome. Am J Clin Pathol 1992, 97:652-655.
71. Nurden A.T., Nurden P., George J.N. Are patients with Glanzmann thrombasthenia and the Bernard-Soulier syndrome protected against atherosclerosis?. Adv Exp Med Biol 2001, 489:13-29.
72. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
73. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003, 120:574-596. British Committee for Standards in Haematology General Haematology Task Force.
74. Matzdorff A., Giagounidis A., Greinacher A., et al. Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a Joint Expert Group of DGHO, DGTI, DTH. Onkologie 2010, 33(Suppl 3):2-20.
75. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2019;115:168-196.
76. Neunert C., Lim W., Crother M., Cohen A., Solberg L., Crowther M.A. American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4197.
77. Loblaw D.A., Perstrud A.A., Somerfield M.R., et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012, 30:3136-3140.
78. Lyman G.H., Khorana A.A., Falanga A., et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25:5490-5505.
79. NCCN Practice Guidelines in Oncology. Venous thromboembolism. V.1.2010. www.nccn.org.
80. Pabinger I., Alt-Epping B., Demarmels Biasutti F., Langer F., Wörmann B., Riess H. Venöse Thrombembolien bei Tumorpatienten - Leitlinie in Kooperation mit der Gesellschaft für Thrombose- und Hämostaseforschung e. V. und der Deutschen Gesellschaft für Palliativmedizin. Hämostaseologie 2011, 31:281-290.
81. Gerber D.E., Grossman S.A., Streiff M.B., et al. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006, 24:1310-1318.
82. Alvarado G., Noor R., Bassett R., et al. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 2012, 22:310-315.